Toxins 2011, 3(4), 409-419; doi:10.3390/toxins3040409
Article

A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines

The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd, Dallas, TX 75390, USA
* Author to whom correspondence should be addressed.
Received: 3 March 2011; in revised form: 30 March 2011 / Accepted: 30 March 2011 / Published: 6 April 2011
(This article belongs to the Special Issue Immunotoxins)
PDF Full-text Download PDF Full-Text [469 KB, Updated Version, uploaded 7 April 2011 08:17 CEST]
The original version is still available [468 KB, uploaded 6 April 2011 17:30 CEST]
Abstract: Precursor B cell acute lymphoblastic leukemia (pre-B ALL) affects five to six thousand adults and almost three thousand children every year. Approximately 25% of the children and 60% of the adults die from their disease, highlighting the need for new therapies that complement rather than overlap chemotherapy and bone marrow transplantation. Immunotherapy is a class of therapies where toxicities and mechanisms of action do not overlap with those of chemotherapy. Because CD19 is a B cell- restricted membrane antigen that is expressed on the majority of pre-B tumor cells, a CD19-based immunotherapy is being developed for ALL. In this study, the anti-tumor activities of immunotoxins (ITs) constructed by conjugating a murine monoclonal antibody (MAb), HD37, or its chimeric (c) construct to recombinant ricin toxin A chain (rRTA) were compared both in vitro using human pre-B ALL and Burkitt’s lymphoma cell lines and in vivo using a disseminated human pre-B ALL tumor cell xenograft model. The murine and chimeric HD37 IT constructs were equally cytotoxic to pre-B ALL and Burkitt’s lymphoma cells in vitro and their use in vivo resulted in equivalent increases in survival of SCID mice with human pre-B ALL tumors when compared with control mice.
Keywords: chimerization; anti-CD19; ricin A chain

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Tsai, L.K.; Pop, L.M.; Liu, X.; Vitetta, E.S. A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines. Toxins 2011, 3, 409-419.

AMA Style

Tsai LK, Pop LM, Liu X, Vitetta ES. A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines. Toxins. 2011; 3(4):409-419.

Chicago/Turabian Style

Tsai, Lydia K.; Pop, Laurentiu M.; Liu, Xiaoyun; Vitetta, Ellen S. 2011. "A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines." Toxins 3, no. 4: 409-419.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert